Unstable angina non ST elevation myocardial infarction long-term medical therapy and secondary prevention: Difference between revisions
Jump to navigation
Jump to search
/* You can read in greater detail about each of the ACC/AHA guidelines for long term medical therapy after UA/NSTEMI as well as for risk factor modification by clicking on the link below:{{cite journal| author=2012 Writing Committee Members. Jneid... |
/* You can read in greater detail about each of the ACC/AHA guidelines for long term medical therapy and risk factor modification after UA/NSTEMI by clicking on the links below:{{cite journal| author=2012 Writing Committee Members. Jneid H, Ander... |
||
| Line 15: | Line 15: | ||
*[[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for antiplatelet therapy|Antiplatelet therapy]] | *[[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for antiplatelet therapy|Antiplatelet therapy]] | ||
*[[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for beta blockers|Beta-blockers]] | *[[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for beta blockers|Beta-blockers]] | ||
*[[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for inhibitors of the RAS|Renin-angiotensin-aldosterone inhibitors]] | *[[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for inhibitors of the RAS|Renin-angiotensin-aldosterone inhibitors]] | ||
* [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for nitroglycerin|Nitroglycerin therapy]] | |||
* [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for CCB|Calcium channel blockers]] | |||
* [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for warfarin therapy|Warfarin therapy]] | [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for lipid management|Lipid management]] | [[Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for blood pressure control|Blood pressure control]] | [[Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for smoking cessation|Smoking cessation]] | [[Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for weight management|Weight management]] | [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for Physical Activity|Physical activity]] | [[Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for patient education|Patient education]] | [[Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for influenza|Influenza]] | [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines depression|Depression]] | [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines Nonsteroidal Anti-Inflammatory Drugs|Nonsteroidal anti-inflammatory drugs]] | [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines hormone therapy|Hormone therapy]] | [[UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines antioxidant vitamins and folic acid|Antioxidant vitamins and folic Acid]] | [[Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines quality care and outcomes|Quality care and outcomes]]''' | |||
Identifying and, when present, treating [[Coronary heart disease risk factors|Category I]] risk factors can be an optimal secondary prevention strategy in patients with UA/NSTEMI. You can read more about general coronary heart disease secondary prevention [[Coronary heart disease secondary prevention|HERE]] | Identifying and, when present, treating [[Coronary heart disease risk factors|Category I]] risk factors can be an optimal secondary prevention strategy in patients with UA/NSTEMI. You can read more about general coronary heart disease secondary prevention [[Coronary heart disease secondary prevention|HERE]] | ||
Revision as of 17:29, 23 January 2013
 |
Intern Survival Guide |
|
Unstable angina / NSTEMI Microchapters |
|
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders |
|
Special Groups |
|
Diagnosis |
|
Laboratory Findings |
|
Treatment |
|
Antitplatelet Therapy |
|
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy |
|
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS |
|
Mechanical Reperfusion |
|
Discharge Care |
|
Case Studies |
|
Unstable angina non ST elevation myocardial infarction long-term medical therapy and secondary prevention On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Overview
Similar to patients with STEMI, patients with UA/NSTEMI also require secondary prevention at the time of discharge. Patients and their families should be educated regarding the specific targets for LDL cholesterol and HDL cholesterol, blood pressure, body mass index (BMI), physical activity, and other appropriate lifestyle modifications.
You can read in greater detail about each of the ACC/AHA guidelines for long term medical therapy and risk factor modification after UA/NSTEMI by clicking on the links below:[1]
- Antiplatelet therapy
- Beta-blockers
- Renin-angiotensin-aldosterone inhibitors
- Nitroglycerin therapy
- Calcium channel blockers
- Warfarin therapy | Lipid management | Blood pressure control | Smoking cessation | Weight management | Physical activity | Patient education | Influenza | Depression | Nonsteroidal anti-inflammatory drugs | Hormone therapy | Antioxidant vitamins and folic Acid | Quality care and outcomes
Identifying and, when present, treating Category I risk factors can be an optimal secondary prevention strategy in patients with UA/NSTEMI. You can read more about general coronary heart disease secondary prevention HERE
References
- ↑ 2012 Writing Committee Members. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR; et al. (2012). "2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. 126 (7): 875–910. doi:10.1161/CIR.0b013e318256f1e0. PMID 22800849.